Overview

* Assembly Biosciences ( ASMB ) Q2 revenue from Gilead collaboration rises to $9.6 mln

* Net loss narrows to $10.2 mln from $11.2 mln year-over-year

Outlook

* Assembly Bio projects cash to fund operations into mid-2026

Result Drivers

* GILEAD COLLABORATION - Increased revenue from expanded research activities with Gilead

* COSTS EASE - R&D expenses decrease largely due to a decrease in spending on ABI-6250 trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$1.33

Q2 Net -$10.20

Income mln

Q2 Basic -$1.33

EPS

Q2 -$11.09

Income mln

From

Operatio

ns

Q2 $20.72

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Assembly Biosciences Inc ( ASMB ) is $31.00, about 39.2% above its August 5 closing price of $18.86

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)